Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Zhang, Xinyi; Cui, Hengqing; Zhang, Wenjun; Li, Zhao‐Shen; Gao, Jie

doi:10.1016/j.bioactmat.2022.10.016

Cited by 23 publications

(20 citation statements)

References 228 publications

(311 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another approach, extracted membranes from tumor cells and E. coli were fused to create a nanoparticulate vaccine containing tumor cell‐derived antigens and pathogen‐associated molecular patterns (PAMPs) found on bacterial membranes 124 . Finally, exosomes derived from tumor cells are an additional option, as they possess excellent biocompatibility and stability along with a capacity to carry therapeutic drugs of varying properties 125,126 …”

Section: Discussion Opportunities and Challengesmentioning

confidence: 99%

Cancer vaccines in the clinic

Janes,

Gottlieb,

Park

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Vaccines are an important tool in the rapidly evolving repertoire of immunotherapies in oncology. Although cancer vaccines have been investigated for over 30 years, very few have achieved meaningful clinical success. However, recent advances in areas such antigen identification, formulation development and manufacturing, combination therapy regimens, and indication and patient selection hold promise to reinvigorate the field. Here, we provide a timely update on the clinical status of cancer vaccines. We identify and critically analyze 360 active trials of cancer vaccines according to delivery vehicle, antigen type, indication, and other metrics, as well as highlight eight globally approved products. Finally, we discuss current limitations and future applications for clinical translation of cancer vaccines.

show abstract

Section: Discussion Opportunities and Challengesmentioning

confidence: 99%

Cancer vaccines in the clinic

Janes,

Gottlieb,

Park

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…They also exhibit distinct tumour characteristics such as resistance to drugs, invasiveness, and tendency to recur. These characteristics of CSCs are being harnessed for stimulating immune cells against cancer cells [ 114 ].…”

Section: Recent Developments In Cancer Immunotherapymentioning

confidence: 99%

Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer

2023

View full text Add to dashboard Cite

Despite advancements in the development of anticancer medications and therapies, cancer still has the greatest fatality rate due to a dismal prognosis. Traditional cancer therapies include chemotherapy, radiotherapy, and targeted therapy. The conventional treatments have a number of shortcomings, such as a lack of selectivity, non-specific cytotoxicity, suboptimal drug delivery to tumour locations, and multi-drug resistance, which results in a less potent/ineffective therapeutic outcome. Cancer immunotherapy is an emerging and promising strategy to elicit a pronounced immune response against cancer. Immunotherapy stimulates the immune system with cancer-specific antigens or immune checkpoint inhibitors to overcome the immune suppressive tumour microenvironment and kill the cancer cells. However, delivery of the antigen or immune checkpoint inhibitors and activation of the immune response need to circumvent the issues pertaining to short lifetimes and effect times, as well as adverse effects associated with off-targeting, suboptimal, or hyperactivation of the immune system. Additional challenges posed by the tumour suppressive microenvironment are less tumour immunogenicity and the inhibition of effector T cells. The evolution of nanotechnology in recent years has paved the way for improving treatment efficacy by facilitating site-specific and sustained delivery of the therapeutic moiety to elicit a robust immune response. The amenability of nanoparticles towards surface functionalization and tuneable physicochemical properties, size, shape, and surfaces charge have been successfully harnessed for immunotherapy, as well as combination therapy, against cancer. In this review, we have summarized the recent advancements made in choosing different nanomaterial combinations and their modifications made to enable their interaction with different molecular and cellular targets for efficient immunotherapy. This review also highlights recent trends in immunotherapy strategies to be used independently, as well as in combination, for the destruction of cancer cells, as well as prevent metastasis and recurrence.

show abstract

“…The imperative to develop potent anti‐tumor strategy has become increasingly urgent, [ 1 ] with the goal of eradicating the recurrence of solid tumors and disseminated metastasis after surgical interventions. [ 2 ] Personalized cancer vaccine, which triggers tumor‐specific cell‐mediated immunity to eliminate tumors, stands out as a particularly promising approach in providing long‐term protection.…”

Section: Introductionmentioning

confidence: 99%

Hybrid Ginseng‐derived Extracellular Vesicles‐Like Particles with Autologous Tumor Cell Membrane for Personalized Vaccination to Inhibit Tumor Recurrence and Metastasis

Wang,

Mu,

Chen

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Personalized cancer vaccines based on resected tumors from patients is promising to address tumor heterogeneity to inhibit tumor recurrence or metastasis. However, it remains challenge to elicit immune activation due to the weak immunogenicity of autologous tumor antigens. Here, a hybrid membrane cancer vaccine is successfully constructed by membrane fusion to enhance adaptive immune response and amplify personalized immunotherapy, which formed a codelivery system for autologous tumor antigens and immune adjuvants. Briefly, the functional hybrid vesicles (HM‐NPs) are formed by hybridizing ginseng‐derived extracellular vesicles‐like particles (G‐EVLPs) with the membrane originated from the resected autologous tumors. The introduction of G‐EVLPs can enhance the phagocytosis of autologous tumor antigens by dendritic cells (DCs) and facilitate DCs maturation through TLR4, ultimately activating tumor‐specific cytotoxic T lymphocytes (CTLs). HM‐NPs can indeed strengthen specific immune responses to suppress tumors recurrence and metastasis including subcutaneous tumors and orthotopic tumors. Furthermore, a long‐term immune protection can be obtained after vaccinating with HM‐NPs, and prolonging the survival of animals. Overall, this personalized hybrid autologous tumor vaccine based on G‐EVLPs provides the possibility of mitigating tumor recurrence and metastasis after surgery while maintaining good biocompatibility.

show abstract

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Cited by 23 publications

References 228 publications

Cancer vaccines in the clinic

Cancer vaccines in the clinic

Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer

Hybrid Ginseng‐derived Extracellular Vesicles‐Like Particles with Autologous Tumor Cell Membrane for Personalized Vaccination to Inhibit Tumor Recurrence and Metastasis

Contact Info

Product

Resources

About